A case report of multiple relapses of Henoch-Schonlein purpura

Afrilia Intan Pratiwi; Sumadiono Sumadiono; Mei Neni Sitaresmi

doi:10.14238/pi63.2.2023.134-8

Afrilia Intan Pratiwi Department of Child Health, Universitas Gadjah Mada Medical School/ Dr. Sardjito Hospital, Yogyakarta, Central Java
Sumadiono Sumadiono Department of Child Health, Universitas Gadjah Mada Medical School/ Dr. Sardjito Hospital, Yogyakarta, Central Java
Mei Neni Sitaresmi Department of Child Health, Universitas Gadjah Mada Medical School/ Dr. Sardjito Hospital, Yogyakarta, Central Java

DOI: https://doi.org/10.14238/pi63.2.2023.134-8

Keywords: Henoch Schonlein Purpura, relapses, corticosteroid

Abstract

Henoch-Schonlein Purpura (HSP) is an acute immunoglobulin A (IgA)–mediated disorder characterized by generalized vasculitis. HSP commonly occurs in children. The annual worldwide incidence is 13-20 per 100,000 children under 17 years of age.^1–3It is characterized by non-thrombocytopenic palpable purpura mostly located on the dependent parts like lower extremities and buttocks, arthralgia/arthritis, bowel angina, and hematuria/proteinuria. HSP pathophysiology is not yet completely understood. Genetic factors are thought to drive the fundamental susceptibility and clinical manifestations. Proposed triggering factors include upper respiratory tract infections, medications, vaccinations, and malignancies. Disease course is usually benign and self-limited. Even though the prognosis is generally good, recurrences or relapses are common within 1 year of initial presentation.⁴

References

Yang YH, Hung CF, Hsu CR, Wang LC, Chuang YH, Lin YT, et al. A nationwide survey on epidemiological characteristics of childhood Henoch-Schönlein purpura in Taiwan. Rheumatology. 2005;44:618–22. DOI: https://doi.org/10.1093/rheumatology/keh544.
2. Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002;360, 1197–1202. https://doi.org/10.1016/S0140-6736(02)11279-7.
3. Yang YH, Yu HH, Chiang BL. The diagnosis and classification of Henoch-Schönlein purpura: An updated review. Vol. 13, Autoimmunity Reviews. 2014;13:355–8. DOI: https://doi.org/10.1016/j.autrev.2014.01.031.
4. Hetland LE, Susrud KS, Lindahl KH, Bygum A. Henoch-schönlein purpura: A literature review. Vol. 97, Acta Dermato-Venereologica. 2017;97:1160–6. DOI: https://doi.org/10.2340/00015555-2733.
5. Byun JW, Song HJ, Kim L, Shin JH, Choi GS. Predictive factors of relapse in adult with Henoch-Schönlein purpura. The American Journal of dermatopathology. 2012;34:139–44. https://doi.org/10.1097/DAD.0b013e3182157f90.
6. Prais D, Amir J, Nussinovitch M. Recurrent Henoch-Schönlein purpura in children. Journal of Clinical Rheumatology. 2007;13:25–8. DOI: https://doi.org/10.1097/01.rhu.0000255692.46165.19.
7. Calvo-Río V, Hernández JL, Ortiz-Sanjuán F, Loricera J, Palmou-Fontana N, González-Vela MC, et al. Relapses in patients with Henoch-Schönlein purpura: Analysis of 417 patients from a single center. Medicine . 2016;95. DOI: https://doi.org/10.1097%2FMD.0000000000004217.
8. Reid-Adam J. Henoch-Schonlein purpura. Pediatrics in review. 2014;35:447–449. DOI: https://doi.org/10.1542/pir.35-10-447.
9. Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis and rheumatism. 1990;33:1114–21. DOI: https://doi.org/10.1002/art.1780330809.
10. Lei WT, Tsai PL, Chu SH, Kao YH, Lin CY, Fang LC, et al. Incidence and risk factors for recurrent Henoch-Schönlein purpura in children from a 16-year nationwide database. Pediatric Rheumatology. 2018;16. DOI: https://doi.org/10.1186/s12969-018-0247-8.
11. González-Gay MA, López-Mejías R, Pina T, Blanco R, Castañeda S. IgA vasculitis: genetics and clinical and therapeutic management. Curr Rheumatol Rep. 2018;20. DOI: https://doi.org/10.1007/s11926-018-0735-3.
12. Shin JI, Park JM, Shin YH, Hwang DH, Kim JH, Lee JS. Predictive factors for nephritis, relapse, and significant proteinuria in childhood Henoch-Schönlein purpura. Scand J Rheumatol. 2006;35:56–60. DOI: https://doi.org/10.1080/03009740510026841.
13. Weiss PF, Feinstein JA, Luan X, Burnham JM, Feudtner C. (2007). Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review. Pediatrics. 2007;120: 1079–87. DOI: https://doi.org/10.1542/peds.2007-0667.
14. Nikibakhsh AA, Mahmoodzadeh H, Karamyyar M, Hejazi S, Noroozi M, Macooie AA, et al. Treatment of complicated Henoch-Schönlein Purpura with mycophenolate mofetil: a retrospective case series report. International Journal of Rheumatology. 2010, Article ID 254316. DOI: https://doi.org/10.1155/2010/254316.
15. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Medical care. 2001;39:800–12. DOI: https://doi.org/10.1097/00005650-200108000-00006.
16. Geist R, Grdisa V, Otley A. Psychosocial issues in the child with chronic conditions. Best practice & research. Clinical gastroenterology. 2003;17:141–52. DOI: https://doi.org/10.1016/s1521-6918(02)00142-7.